EICHOR
● Completed
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
Condition: Dry Eye Disease · Sponsor: Bausch & Lomb Incorporated
About this study
A 4-Week, Randomized, Double-Masked, Parallel-Group, Active-Controlled, Multicenter Study Evaluating Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination Administered Twice Daily on Signs and Symptoms of Dry Eye Disease
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (32)
| Eye Doctors of Arizona, PLLC | Phoenix, Arizona, United States | — |
| Global Research Management, Inc. | Glendale, California, United States | — |
| SoCal Eye - Lakewood Clinic | Long Beach, California, United States | — |
| LoBue Laser and Eye Medical Center | Murrieta, California, United States | — |
| Eye Research Foundation, Inc. | Newport Beach, California, United States | — |
| Wolstan and Goldberg Eye Associates | Torrance, California, United States | — |
| Segal Drug Trials/Office of Bruce A Segal, MD | Delray Beach, Florida, United States | — |
| Bowden Eye and Associates | Jacksonville, Florida, United States | — |
| Shettle Eye Research, Inc | Largo, Florida, United States | — |
| Clayton Eye Clinical Research, LLC | Morrow, Georgia, United States | — |
| Midwest Cornea Associates LLC | Carmel, Indiana, United States | — |
| Kannarr Eye Care, LLC | Pittsburg, Kansas, United States | — |
+ 20 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.